Hao Chen

Dr. Hao Chen


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
JWJianyu Wang
Jianyu Wang
YWYuhang Wang
Yuhang Wang
HCHao Chen
Hao Chen
HZHan Zhang
Han Zhang
XZXiaojiang Zhao
Xiaojiang Zhao
DSDaqiang Sun
Daqiang Sun
Background/Objectives: The aim of this study was to evaluate the performance of the Node-RADS scoring system for predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC) after neoadjuvant therapy and to assess its prognostic value for overall survival (OS) and event-free survival (EFS). Methods: A total of 247 patients with non-small cell lung cancer (NSCLC) from three centers who underwent surgery after neoadjuvant therapy were retrospectively enrolled. Post-treatment Node-RADS scores were reassessed by radiologists based on preoperative contrast-enhanced CT images. Logistic regression analysis was used to evaluate the predictive value of Node-RADS for postoperative pathological lymph node metastasis, while Cox regression analysis was performed to assess its associations with OS and EFS. Kaplan–Meier analysis was used to compare survival differences among different Node-RADS risk groups. Results: A total of 247 patients were included in this study, comprising 211 men and 36 women, with a mean age of 63.40 ± 7.58 years. Post-treatment Node-RADS score was significantly associated with both OS and EFS. In multivariable Cox regression analysis, Node-RADS remained independently associated with OS (HR = 1.79, 95% CI: 1.50–2.15, p < 0.001) and EFS (HR = 1.41, 95% CI: 1.23–1.62, p < 0.001). Using a Node-RADS score of 3 as the cutoff value, patients in the high-risk group had significantly worse OS and EFS than those in the low-risk group (both p < 0.01). For the prediction of lymph node metastasis, the inclusion of post-treatment Node-RADS markedly improved the discriminatory performance of the model, with an AUC of 0.769, a sensitivity of 46.2%, and a specificity of 87.6%. Conclusions: The Node-RADS score may provide useful imaging information for patient-level assessment of residual lymph node metastasis risk and survival stratification in patients with NSCLC after neoadjuvant therapy. These findings suggest that the scoring system may support patient-level post-treatment risk assessment.

8 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Feng WangFeng Wang
Feng Wang
XYXiangyang Yu
Xiangyang Yu
HCHao Chen
Hao Chen
DYDongjie Yan
Dongjie Yan
LYLei Yang
Lei Yang
YHYi Han
Yi Han
Background/Objectives: Major pathological response (MPR) has been suggested as a potential surrogate marker for assessing the efficacy of neoadjuvant therapy. However, its prognostic value and association with postoperative recurrence patterns remain unclear in patients with locally advanced oesophageal squamous cell carcinoma (ESCC) treated with neoadjuvant immunochemotherapy. This multicentre study aimed to investigate the relationship between MPR status, survival outcomes, and recurrence characteristics in this population. Methods: A total of 305 patients with locally advanced ESCC who received neoadjuvant immunochemotherapy followed by surgical resection at four medical centres in China between December 2019 and April 2024 were retrospectively enrolled in this study. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were analyzed using Cox proportional hazards regression models. Propensity score matching (PSM) was performed to balance baseline characteristics between patients with and without MPR, and survival outcomes and postoperative recurrence patterns were subsequently compared. Results: Among the 305 patients, 115 (37.7%) achieved MPR. Multivariate analysis identified MPR and the number of neoadjuvant treatment cycles as independent prognostic factors for both OS and RFS (p < 0.05). After PSM, patients with MPR showed significantly improved OS and RFS compared with those without (p < 0.05). Postoperative recurrence occurred less frequently in the MPR group than in the non-MPR group (13.9% vs. 42.1%, respectively; p < 0.05), with reductions in both locoregional and distant recurrence. Conclusions: In patients with locally advanced ESCC receiving neoadjuvant immunochemotherapy and surgery, achieving MPR is associated with improved survival outcomes and a lower risk of postoperative recurrence. MPR may serve as a useful prognostic indicator for this population.

25 January 2026 in Research Square
Verified
Preprint
Open access
PDF file
HCHao Chen
Hao Chen
DYDongjie Yan
Dongjie Yan
CLChunming Liu
Chunming Liu
LZLanjun Zhang
Lanjun Zhang
YHYi Han
Yi Han
Feng WangFeng Wang
Feng Wang
Background Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) being the most common type. Systematic lymph node dissection (SLND) is a standard procedure for NSCLC, but the necessity of routine interlobar lymph node dissection (ILND) in early-stage disease, particularly in stage IB NSCLC, remains debated. While ILND can be technically performed, its benefit in improving overall survival (OS) or recurrence-free survival (RFS) is unclear. The need for routine ILND remains controversial, with limited studies addressing its role in early-stage disease. This study aimed to assess whether ILND contributes to better survival outcomes in stage IB NSCLC. Methods We retrospectively analyzed 597 IB-stage NSCLC patients who underwent radical surgery for lung cancer at Sun Yat-Sen University Cancer Center from 1999 to 2009. We used the Cox proportional hazards regression model to analyze prognostic factors. After propensity-score matching (PSM), 458 patients were selected. We applied the Kaplan-Meier method and log-rank test to compare OS and RFS. Results Among 597 patients included in the study, 262 did not have ILND, while 335 did. According to whether the interlobar lymph nodes were dissected, 597 patients were divided into two groups. Significant differences were found between the two groups in laterality, number of dissected lymph node stations, and number of dissected lymph nodes (P < 0.05). Univariate and multivariate Cox analyses by the Cox proportional hazards model showed that age, family history of malignant tumors, and number of dissected lymph nodes were prognostic factors for OS (P < 0.05). For RFS, age and number of dissected lymph nodes were significant (P < 0.05). ILND was not associated with OS or RFS. After PSM, survival analysis using the Kaplan-Meier method and log-rank test showed no statistical association between ILND and OS or RFS (P > 0.05). Conclusion In stage IB NSCLC patients, ILND is not significantly associated with OS or RFS. Routine ILND is not necessary for early-stage NSCLC.